Turn Therapeutics (NASDAQ:TTRX) Stock Rating Lowered by Wall Street Zen

Turn Therapeutics (NASDAQ:TTRX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday, Wall Street Zen reports.

A number of other equities analysts have also commented on the stock. Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a report on Monday, July 20th. WBB Securities raised Turn Therapeutics from a “sell” rating to a “hold” rating and set a $10.00 price objective on the stock in a research note on Friday, October 23rd. Finally, Lucid Cap Mkts upgraded Turn Therapeutics to a “strong-buy” rating in a report on Thursday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.00.

Turn Therapeutics Trading Up 3.3%

NASDAQ TTRX opened at $9.79 on Friday. The stock has a market cap of $298.92 million and a PE ratio of -33.76. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $16.45. The company’s 50-day moving average price is $11.70 and its 200-day moving average price is $7.16. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 8.83.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.21) earnings per share for the quarter. Equities research analysts forecast that Turn Therapeutics will post -0.40 earnings per share for the current year.

Institutional Investors Weigh In On Turn Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. SteelPeak Wealth LLC increased its holdings in shares of Turn Therapeutics by 0.7% during the third quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock valued at $3,616,000 after acquiring an additional 1,819 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new stake in Turn Therapeutics in the 3rd quarter worth approximately $40,000. Bank of America Corp DE acquired a new stake in Turn Therapeutics in the 2nd quarter worth approximately $103,000. Jefferies Financial Group Inc. acquired a new stake in Turn Therapeutics in the 2nd quarter worth approximately $119,000. Finally, Bridgewater Advisors Inc. purchased a new stake in Turn Therapeutics during the 2nd quarter worth approximately $242,000.

Turn Therapeutics Company Profile

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.